Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NRX Pharmaceuticals (NRXP) Gains from Investment Securities (2024 - 2025)

NRX Pharmaceuticals (NRXP) has disclosed Gains from Investment Securities for 2 consecutive years, with -$8.1 million as the latest value for Q4 2025.

  • Quarterly Gains from Investment Securities fell 4779.31% to -$8.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $5.5 million through Dec 2025, changed N/A year-over-year, with the annual reading at $126343.0 for FY2025, N/A changed from the prior year.
  • Gains from Investment Securities for Q4 2025 was -$8.1 million at NRX Pharmaceuticals, down from $5.0 million in the prior quarter.
  • The five-year high for Gains from Investment Securities was $8.5 million in Q2 2025, with the low at -$8.1 million in Q4 2025.